Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Calvert

Showing results (131-140 of 220) with videos related to

Pageof 22
Sort By:
European Journal of Cancer & Clinical Oncology|April 1, 1988
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancerB M Cantwell, V Macaulay, A L Harris, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)D L Alison, D R Newell, C Sessa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalationB J Foster, D R Newell, M A Graham, et al.
European Journal of Cancer|May 1, 1980
Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistanceA H Calvert, T R Jones, P J Dady, et al.
Cancer Research|October 15, 1991
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical studyA L Jackman, G A Taylor, W Gibson, et al.
Cancer Treatment Reports|January 1, 1981
Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical studyP J Dady, G A Taylor, J F Muindi, et al.
British Journal of Cancer|December 1, 1987
Tumour necrosis factor in man: clinical and biological observationsP Selby, S Hobbs, C Viner, et al.
Oncology|January 1, 1978
Improved results in combination chemotherapy of head and neck cancer using a kinetically-based approach: a randomised study with and without adriamycinL A Price, B T Hill, A H Calvert, et al.
Pageof 22

Showing results (131-140 of 220) with videos related to

Sort By:
Pageof 22
European Journal of Cancer & Clinical Oncology|April 1, 1988
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancerB M Cantwell, V Macaulay, A L Harris, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)D L Alison, D R Newell, C Sessa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalationB J Foster, D R Newell, M A Graham, et al.
European Journal of Cancer|May 1, 1980
Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistanceA H Calvert, T R Jones, P J Dady, et al.
Cancer Research|October 15, 1991
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical studyA L Jackman, G A Taylor, W Gibson, et al.
Cancer Treatment Reports|January 1, 1981
Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical studyP J Dady, G A Taylor, J F Muindi, et al.
British Journal of Cancer|December 1, 1987
Tumour necrosis factor in man: clinical and biological observationsP Selby, S Hobbs, C Viner, et al.
Oncology|January 1, 1978
Improved results in combination chemotherapy of head and neck cancer using a kinetically-based approach: a randomised study with and without adriamycinL A Price, B T Hill, A H Calvert, et al.
Pageof 22